Adagio Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

29.10.24	Invivyd Announces Phase 3 Exploratory Clinical Efficacy Data Regarding Pemgarda, Prel. Q3 Results (RTTNews)
27.08.24	Invivyd Announces Positive 180-day Clinical Efficacy Data From CANOPY Phase 3 Trial Of Pemivibart (RTTNews)
31.05.24	Invivyd Gains Alignment With FDA On Rapid Pathway For Options Against Symptomatic COVID-19 (RTTNews)
12.04.24	Invivyd Appoints Jeremy Gowler As Interim CEO As Dave Hering Resigns (RTTNews)
05.09.23	Invivyd Appoints William Duke As New CFO (RTTNews)
30.03.23	IVVD FINAL DEADLINE ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Ac... (PR Newswire)
24.03.23	IVVD FINAL DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities... (PR Newswire)
17.03.23	ROSEN, A LEADING LAW FIRM, Encourages Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - I... (PR Newswire)
09.03.23	ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IVVD, ADGI (PR Newswire)
03.03.23	ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - IVVD, ADGI (PR Newswire)
22.02.23	ROSEN, A TOP RANKED LAW FIRM, Encourages Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IVVD, ADGI (PR Newswire)
16.02.23	ROSEN, LEADING TRIAL ATTORNEYS, Encourages Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IVVD, ADGI (PR Newswire)
10.02.23	ROSEN, A TOP RANKED LAW FIRM, Encourages Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IVVD, ADGI (PR Newswire)
03.02.23	ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IVVD, ADGI (PR Newswire)
05.07.22	Adagio Elevates Interim Chief Executive David Hering To Permanent CEO (RTTNews)
22.06.22	Pre-market Movers: CRDL, DNAY, AMBA, ANGH, ARR… (RTTNews)
31.03.22	Adagio Therapeutics gibt bekannt, dass ADG20 (Adintrevimab) der erste monoklonale Antikörper ist, der die primären Endpunkte der Prophylaxe vor und nach Exposition sowie der Behandlung von COVID-19 mi (GlobeNewswire)
30.03.22	Adagio Therapeutics Says Its Investigational Drug For Covid-19 Met Primary Endpoints (RTTNews)
30.03.22	Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for (GlobeNewswire)
14.01.22	Adagio Therapeutics legt zusammenfassende Ergebnisse zur neutralisierenden Wirkung von ADG20 gegenüber SARS-CoV-2-Varianten vor und stellt Initiativen zur Bekämpfung von Omikron vor (GlobeNewswire)
12.01.22	Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron (GlobeNewswire)
22.12.21	Pre-market Movers: BRTX, RCAT, AVCT, ACST, DBVT… (RTTNews)
21.12.21	Pre-market Movers: ARDS, RELI, ALDX, QNRX, AQST… (RTTNews)
20.12.21	Top Biotech IPOs Of 2021 That Soared As Much As 500% (RTTNews)
17.12.21	Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science Companies (PR Newswire)
17.12.21	Pre-market Movers: GNFT, ABEO, SPRB, IO, CERN… (RTTNews)
14.12.21	Adagio Therapeutics vermeldet eine verminderte neutralisierende Wirkung von ADG20 in vitro gegenüber der SARS-CoV-2-Variante Omikron (GlobeNewswire)
14.12.21	Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 Variant (GlobeNewswire)
30.11.21	Adagio Therapeutics meldet, dass keine der Mutationen der SARS-CoV-2-Variante Omikron in vitro mit einer Flucht vor der ADG20-Neutralisierung in Verbindung gebracht wird (GlobeNewswire)
29.11.21	Adagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Escape from ADG20 Neutralization In Vitro (GlobeNewswire)
16.11.21	Adagio Therapeutics veröffentlicht Update für ADG20-COVID-19-Antikörperprogramm und gibt Finanzergebnisse für das dritte Quartal 2021 bekannt (GlobeNewswire)
15.11.21	Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results (GlobeNewswire)
19.10.21	Adagio Therapeutics kündigt neue In-vitro-Daten zur umfassenden Neutralisationswirkung von ADG20 gegenüber allen bekannten SARS-CoV-2-Varianten an (GlobeNewswire)
19.10.21	Adagio Therapeutics Announces New In Vitro Data Highlighting Broad and Potent Neutralization of ADG20 Against All Known SARS-CoV-2 Variants (GlobeNewswire)
30.09.21	Adagio Therapeutics kündigt neue Daten über Potenzial von ADG20 zur Behandlung und Prävention von COVID-19 an (GlobeNewswire)
29.09.21	Adagio Says New Data Highlight Potential Of ADG20 For Treatment And Prevention Of Covid-19 (RTTNews)
29.09.21	Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19 (GlobeNewswire)
10.09.21	Adagio Therapeutics Expands Patient Population In ADG20 Trial For COVID-19 (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Adagio Therapeutics Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten